Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization partnership for Sysmex’s Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.
